In this week's View, Dr. Eagle looks at the potential role of genetics in predicting risk in people with aortic disease. He then compares plant and animal fat intake in overall cardiovascular disease outcomes. Finally, Dr. Eagle discusses a clinical consensus statement on the management of cardiac sarcoidosis from the European community.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure (HF). He then explores the eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed HF. Finally, Dr. Eagle discusses a systematic review of clinical trials investigating the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) for advanced chronic kidney disease (CKD).

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health. Finally, Dr. Eagle discusses a national analysis of the timing of noncardiac surgery following transcatheter aortic valve replacement (TAVR): is there an optimal time for surgery after TAVR?

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a prospective multicenter cohort study that examined early and late aortic-related mortality and rupture after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms. He then explores periprocedural mortality in patients having PCI and a rise in biomarkers. Finally, Dr. Eagle discusses a systemic review and meta-analysis of lipoprotein(a) and calcific aortic valve stenosis progression.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF). He then explores a randomized trial that investigates the effects of implantable cardioverter-defibrillator (ICD) leads on the tricuspid valve and right ventricle. Finally, Dr. Eagle discusses the effects of rapid up-titration of neurohormonal blockade in patients with acute decompensated HF.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses a state-of-the-art review on iron repletion for patients with heart failure and iron deficiency. He then explores the diagnosis and management of ventricular septal defect complicating acute myocardial infarction. Finally, Dr. Eagle discusses practical guidance for hemodynamic assessment by right heart catheterization in management of heart failure.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the clinical impact of early rhythm control and healthy lifestyles in patients with atrial fibrillation, then explores the use of low-dose aspirin in the prevention of atherosclerotic cardiovascular disease. Finally, Dr. Eagle discusses the association of autoimmune diseases with coronary atherosclerosis and ischemic events.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at office measurement vs. ambulatory blood pressure monitoring and its associations with mortality in patients with or without diabetes. Dr. Eagle then reviews two related articles: a report in JACC on Artificial Intelligence and cardiovascular care, and a recent article from The Lancet on inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease in which AI played an important role.

Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure. Finally, Dr. Eagle shares some thoughts on an analysis from the PARTNER2-S3 registry on the predictors and five-year clinical outcomes of pacemakers after TAVR.

Subscribe to Eagle's Eye View